| Aug 22 | Aug 21 | |
|---|---|---|
| Income Statement | ||
| Total Revenue | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 |
| Operating Income | $ -764.56K | $ -1.76K |
| EBITDA | $ -764.56K | $ -1.76K |
| Net Income | $ -764.71K | $ -1.75K |
| Balance Sheet | ||
| Cash & Short-Term Investments | $ 4.21K | $ 1.13K |
| Total Assets | $ 4.21K | $ 900.00 |
| Total Debt | $ 10.27K | $ 0.00 |
| Net Debt | $ 6.06K | $ -1.13K |
| Total Liabilities | $ 17.50K | $ 0.00 |
| Stockholders' Equity | $ -13.28K | $ 900.00 |
| Cash Flow | ||
| Free Cash Flow | $ -6.18K | $ -1.75K |
| Operating Cash Flow | $ -6.18K | $ -1.75K |
| Investing Cash Flow | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 10.40K | $ 0.00 |
Canopus Biopharma Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.